266 related articles for article (PubMed ID: 3058875)
1. A new biomarker in monitoring breast cancer: CA 549.
Beveridge RA; Chan DW; Bruzek D; Damron D; Bray KR; Gaur PK; Ettinger DS; Rock RC; Shurbaji MS; Kuhajda FP
J Clin Oncol; 1988 Dec; 6(12):1815-21. PubMed ID: 3058875
[TBL] [Abstract][Full Text] [Related]
2. Monitoring breast cancer with CA 549.
Chan DW; Beveridge RA; Bruzek DJ; Damron DJ; Bray KR; Gaur PK; Ettinger DS; Rock RC
Clin Chem; 1988 Oct; 34(10):2000-4. PubMed ID: 3168211
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
Colomer R; Ruibal A; Salvador L
Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
[TBL] [Abstract][Full Text] [Related]
4. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases.
Colomer R; Ruibal A; Genollá J; Rubio D; Del Campo JM; Bodi R; Salvador L
Breast Cancer Res Treat; 1989 Mar; 13(2):123-33. PubMed ID: 2730960
[TBL] [Abstract][Full Text] [Related]
5. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
6. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
Safi F; Kohler I; Röttinger E; Beger H
Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
[TBL] [Abstract][Full Text] [Related]
7. The value of MCA, CA 15-3, CEA and CA-125 for discrimination between metastatic breast cancer and adenocarcinoma of other primary sites.
De Wit R; Hoek FJ; Bakker PJ; Veenhof CH
J Intern Med; 1991 May; 229(5):463-6. PubMed ID: 2040873
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer.
Rasoul-Rockenschaub S; Zielinski CC; Kubista E; Vavra N; Pospischil E; Staffen A; Czerwenka K; Aiginger P; Spona J
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1067-72. PubMed ID: 2759162
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma.
Verdi CJ; Ahmann FR; Schifman RB; Elvick AL; Ahmann ME; Marx PC
Cancer; 1993 Jun; 71(11):3625-32. PubMed ID: 8490911
[TBL] [Abstract][Full Text] [Related]
11. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
Hayes DF; Zurawski VR; Kufe DW
J Clin Oncol; 1986 Oct; 4(10):1542-50. PubMed ID: 2428949
[TBL] [Abstract][Full Text] [Related]
12. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
14. [The value of tumor markers CA 15-3 and CEA in breast cancer].
Buck I; Lindner C; Böge K; Kitschke HJ
Arch Gynecol Obstet; 1989; 245(1-4):674-7. PubMed ID: 2802753
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic significance of the tumour markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer.
Kandylis K; Vassilomanolakis M; Baziotis N; Papadimitriou A; Tsoussis S; Ferderigou A; Efremidis AP
Ann Oncol; 1990 Nov; 1(6):435-8. PubMed ID: 2083187
[TBL] [Abstract][Full Text] [Related]
16. [Tumor markers in breast cancer: on the diagnostic value of serum determinations in clinical freedom from tumor and manifest disease].
Günczler P; Ogris E; Maca S; Danmayr E
Onkologie; 1989 Oct; 12(5):209-14. PubMed ID: 2685686
[TBL] [Abstract][Full Text] [Related]
17. Serological markers for metastatic breast cancer.
Ng JS; Sturgeon CM; Seth J; Paterson GM; Roulston JE; Leonard RC
Dis Markers; 1993 Dec; 11(5-6):217-23. PubMed ID: 8082311
[TBL] [Abstract][Full Text] [Related]
18. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
Eur J Cancer; 1995 Sep; 31A(10):1615-21. PubMed ID: 7488411
[TBL] [Abstract][Full Text] [Related]
19. CEA and CA 15-3 in primary and recurrent breast cancer.
O'Dwyer PJ; Duffy MJ; O'Sullivan F; McDermott E; Losty P; O'Higgins NJ
World J Surg; 1990; 14(5):562-5; discussion 565-6. PubMed ID: 2238654
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]